SP1017

a non-ionic drug carrier comprising two amphiphilic block polymers (pluronic L61 & F127); the copolymers when combined constitute an effective carrier system with high thermodynamic stability & low toxicity

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Alakhova, Daria Y: 1 article (01/2019)
2.	Bronich, Tatiana K: 1 article (01/2019)
3.	Faber, Edward A: 1 article (01/2019)
4.	Hu, Hangting: 1 article (01/2019)
5.	Kabanov, Alexander V: 1 article (01/2019)
6.	Liu, Tong: 1 article (01/2019)
7.	Olou, Appolinaire A: 1 article (01/2019)
8.	Osna, Natalia A: 1 article (01/2019)
9.	Petrosyan, Armen: 1 article (01/2019)
10.	Singh, Pankaj K: 1 article (01/2019)

Related Diseases

1.	Disease Progression 01/01/2019 - "Using a human MM/SCID mice model, the combination of bortezomib and SP1017 exerted enhanced antitumor efficacy as compared to bortezomib alone, delaying disease progression, but without additional toxicity. "
2.	Hypersensitivity (Allergy) 06/20/2003 - "The co-injection of pVAX-gag and pNGVL3-hFlex, formulated in SP1017, significantly increase delayed-type hypersensitivity responses and the numbers of antigen (Ag)-specific interferon-gamma secreting T cells in the spleen (Enzyme Linked Immune Spot (ELISpot) assay), compared to mice immunized with pVAX-gag formulated in SP1017 alone. "

Related Drugs and Biologics

1.	Interferon-gamma (Interferon, gamma)
2.	Enzymes
3.	Antigens
4.	Bortezomib (Velcade)